VAX-31 Outperforms Pfizer and Merck Vaccines in Early-Stage Trial, Analysts Predict Displacement

  • Vaxcyte’s stock surges 33% following positive trial results for its pneumococcal vaccine candidate VAX-31
  • VAX-31 shows superior immunogenicity compared to Pfizer’s Prevnar 20 and Merck’s Capvaxive in Phase 1/2 study
  • Mizuho analysts predict potential displacement of Pfizer and Merck vaccines with a total addressable market peak sales of $88 billion
  • VAX-31 to enter Phase 3 trial for adults in mid-2025, mid-stage trial for infants in Q1 2025
  • Positive safety and immunogenicity results indicate Vaxcyte’s platform’s potential for broad-spectrum PCVs

Vaxcyte Inc.’s stock skyrocketed by 33% after revealing promising results from an early-stage trial of its pneumococcal conjugate vaccine candidate, VAX-31. The vaccine aims to prevent invasive pneumococcal disease (IPD) and non-invasive PD in adults aged 50 and older. With superior immunogenicity compared to Pfizer’s Prevnar 20 and Merck’s Capvaxive, VAX-31 is set for a Phase 3 trial in mid-2025 and a mid-stage trial for infants in Q1 2025. Mizuho analysts believe the vaccine could displace Pfizer and Merck’s vaccines, with a total addressable market peak sales of $88 billion. VAX-31’s safety profile is similar to Prevnar 20, and its site-specific carrier-sparing platform demonstrates potential for broad-spectrum PCVs against circulating and historical strains. The company plans to move to Phase 3 trial for adults in mid-2025 with topline data expected by 2026.

Image Credits: no
Factuality Level: 9
Factuality Justification: The article provides accurate and objective information about Vaxcyte Inc.’s vaccine candidate VAX031’s positive results from a Phase 1/2 trial, its planned future trials, and the potential market for pneumococcal vaccines. It also includes expert opinions on the stock’s performance and market potential.
Noise Level: 7
Noise Justification: The article provides relevant information about Vaxcyte Inc.’s positive results from an early-stage trial of its vaccine candidate VAX031 and its plans for future trials. However, it includes some promotional language from the company and analysts’ opinions without providing a critical analysis or questioning their validity.
Public Companies: Vaxcyte Inc. (PCVX), Pfizer Inc. (PFE), Merck & Co., Inc. (MRK)
Key People: Grant Pickering (Chief Executive and Co-founder of Vaxcyte), Salim Syed (Analyst at Mizuho)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Vaxcyte Inc.’s stock soared 33%, impacting financial markets and companies in the vaccine industry.
Financial Rating Justification: The article discusses positive results from an early-stage trial of Vaxcyte’s vaccine candidate, leading to a significant increase in the company’s stock price and potential market impact on the vaccine industry.
Presence Of Extreme Event: No
Nature Of Extreme Event: Other
Impact Rating Of The Extreme Event: Minor
Extreme Rating Justification: No extreme event mentioned in the text, but the stock of Vaxcyte Inc. soared 33% due to positive results from a vaccine trial.
Move Size: 33%
Sector: Healthcare
Direction: Up
Magnitude: Large
Affected Instruments: Stocks

Reported publicly: www.marketwatch.com www.barrons.com